These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 15201575)

  • 1. Infliximab: mechanism of action beyond TNF-alpha neutralization in inflammatory bowel disease.
    Kirman I; Whelan RL; Nielsen OH
    Eur J Gastroenterol Hepatol; 2004 Jul; 16(7):639-41. PubMed ID: 15201575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased production of granulocyte-macrophage colony-stimulating factor in Crohn's disease--a possible target for infliximab treatment.
    Agnholt J; Kelsen J; Brandsborg B; Jakobsen NO; Dahlerup JF
    Eur J Gastroenterol Hepatol; 2004 Jul; 16(7):649-55. PubMed ID: 15201577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of etanercept and infliximab on the production of tumour necrosis factor alpha, interferon-gamma and GM-CSF in in vivo activated intestinal T lymphocyte cultures.
    Agnholt J; Dahlerup JF; Kaltoft K
    Cytokine; 2003 Aug; 23(3):76-85. PubMed ID: 12906870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease.
    Van den Brande JM; Braat H; van den Brink GR; Versteeg HH; Bauer CA; Hoedemaeker I; van Montfrans C; Hommes DW; Peppelenbosch MP; van Deventer SJ
    Gastroenterology; 2003 Jun; 124(7):1774-85. PubMed ID: 12806611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of antitumour necrosis factor clinical efficacy by real-time visualisation of apoptosis in patients with Crohn's disease.
    Van den Brande JM; Koehler TC; Zelinkova Z; Bennink RJ; te Velde AA; ten Cate FJ; van Deventer SJ; Peppelenbosch MP; Hommes DW
    Gut; 2007 Apr; 56(4):509-17. PubMed ID: 17082252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease.
    Di Sabatino A; Ciccocioppo R; Cinque B; Millimaggi D; Morera R; Ricevuti L; Cifone MG; Corazza GR
    Gut; 2004 Jan; 53(1):70-7. PubMed ID: 14684579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TNF-alpha blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation: a novel anti-inflammatory mechanism of infliximab in Crohn's disease.
    Danese S; Sans M; Scaldaferri F; Sgambato A; Rutella S; Cittadini A; Piqué JM; Panes J; Katz JA; Gasbarrini A; Fiocchi C
    J Immunol; 2006 Feb; 176(4):2617-24. PubMed ID: 16456024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review article: targeting TNF alpha as a key cytokine in the inflammatory processes of Crohn's disease--the mechanisms of action of infliximab.
    van Deventer SJ
    Aliment Pharmacol Ther; 1999 Sep; 13 Suppl 4():3-8; discussion 38. PubMed ID: 10597333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti tumour necrosis-alpha therapy increases the number of FOXP3 regulatory T cells in children affected by Crohn's disease.
    Ricciardelli I; Lindley KJ; Londei M; Quaratino S
    Immunology; 2008 Oct; 125(2):178-83. PubMed ID: 18422560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction of CD68+ macrophages and decreased IL-17 expression in intestinal mucosa of patients with inflammatory bowel disease strongly correlate with endoscopic response and mucosal healing following infliximab therapy.
    Caprioli F; Bosè F; Rossi RL; Petti L; Viganò C; Ciafardini C; Raeli L; Basilisco G; Ferrero S; Pagani M; Conte D; Altomare G; Monteleone G; Abrignani S; Reali E
    Inflamm Bowel Dis; 2013; 19(4):729-39. PubMed ID: 23448791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of infliximab on apoptosis and reverse signaling of monocytes from healthy individuals and patients with Crohn's disease.
    Ringheanu M; Daum F; Markowitz J; Levine J; Katz S; Lin X; Silver J
    Inflamm Bowel Dis; 2004 Nov; 10(6):801-10. PubMed ID: 15626899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-TNF therapy for Crohn's disease: a perspective (infliximab is not the drug we have been waiting for).
    Shanahan F
    Inflamm Bowel Dis; 2000 May; 6(2):137-9. PubMed ID: 10833074
    [No Abstract]   [Full Text] [Related]  

  • 13. Transcending conventional therapies: the role of biologic and other novel therapies.
    Sandborn WJ
    Inflamm Bowel Dis; 2001 May; 7 Suppl 1():S9-16. PubMed ID: 11380043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimizing anti-TNF treatment in inflammatory bowel disease.
    Rutgeerts P; Van Assche G; Vermeire S
    Gastroenterology; 2004 May; 126(6):1593-610. PubMed ID: 15168370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High serum tumor necrosis factor-alpha levels are associated with lack of response to infliximab in fistulizing Crohn's disease.
    Martínez-Borra J; López-Larrea C; González S; Fuentes D; Dieguez A; Deschamps EM; Pérez-Pariente JM; López-Vázquez A; de Francisco R; Rodrigo L
    Am J Gastroenterol; 2002 Sep; 97(9):2350-6. PubMed ID: 12358255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-TNF alpha: new therapy for Crohn's disease.
    Mikula CA
    Gastroenterol Nurs; 1999; 22(6):245-8. PubMed ID: 10855120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-response to infliximab may be due to innate neutralizing anti-tumour necrosis factor-alpha antibodies.
    Ebert EC; Das KM; Mehta V; Rezac C
    Clin Exp Immunol; 2008 Dec; 154(3):325-31. PubMed ID: 18826498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infliximab as disease-modifying therapy.
    D'Haens GR
    Eur J Gastroenterol Hepatol; 2003 Mar; 15(3):233-7. PubMed ID: 12610316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infliximab induced T lymphocyte apoptosis in Crohn's disease.
    van den Brande J; Hommes DW; Peppelenbosch MP
    J Rheumatol Suppl; 2005 Mar; 74():26-30. PubMed ID: 15742461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway.
    Lügering A; Schmidt M; Lügering N; Pauels HG; Domschke W; Kucharzik T
    Gastroenterology; 2001 Nov; 121(5):1145-57. PubMed ID: 11677207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.